文献速递基础与转化研究临床试验与 GCP

骨内注射造血干细胞基因治疗输血依赖型β地中海贫血

Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
PubMed 文献 · Nat Med · 2019-01-21

一项1/2期试验对3例成人和6例儿童β0或严重β+突变患者经骨内注射GLOBE慢病毒载体转导的自体HSC,实现快速造血恢复和多克隆多系植入,成人输血需求减少,4例可评估儿童中3例脱离输血。

要点

  • 骨内注射GLOBE载体转导自体HSC可实现多克隆多系植入且无克隆优势。
  • 成人输血需求减少,4例可评估儿童中3例末次随访时脱离输血。
  • 年轻年龄和再增殖造血细胞中较高VCN持续与更好结局相关。

核心结论

  • 骨内注射GLOBE载体转导的自体HSC基因治疗在成人及儿童输血依赖型β地中海贫血中可实现多克隆多系植入并减少输血需求。

研究设计与样本

  • 1/2期试验(NCT02453477)纳入3例成人和6例儿童β0或严重β+突变患者,经骨内注射GLOBE慢病毒载体转导的自体HSC。

主要发现

  • 1年时造血祖细胞中载体标记中位37.5%(范围12.6-76.4%),红系前体细胞VCN中位0.58(范围0.10-1.97),无克隆优势。
  • 成人输血需求减少。
  • 4例可评估儿童中3例基因治疗后脱离输血,末次随访时输血独立。
  • 年轻年龄和再增殖造血细胞中较高VCN持续与更好结局相关。

临床怎么用

  • 该策略可能为缺乏全相合供者的输血依赖型β地中海贫血患者提供自体HSC基因治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ß-thalassemia is caused by ß-globin gene mutations resulting in reduced (β+) or absent (β0) hemoglobin production. Patient life expectancy has recently increased, but the need for chronic transfusions in transfusion-dependent thalassemia (TDT) and iron chelation impairs quality of life1. Allogeneic hematopoietic stem cell (HSC) transplantation represents the curative treatment, with thalassemia-free survival exceeding 80%. However, it is available to a minority of patients and is associated with morbidity, rejection and graft-versus-host disease2. Gene therapy with autologous HSCs modified to express ß-globin represents a potential therapeutic option. We treated three adults and six children with ß0 or severe ß+ mutations in a phase 1/2 trial ( NCT02453477 ) with an intrabone administration of HSCs transduced with the lentiviral vector GLOBE. Rapid hematopoietic recovery with polyclonal multilineage engraftment of vector-marked cells was achieved, with a median of 37.5% (range 12.6-76.4%) in hematopoietic progenitors and a vector copy number per cell (VCN) of 0.58 (range 0.10-1.97) in erythroid precursors at 1 year, in absence of clonal dominance. Transfusion requirement was reduced in the adults. Three out of four evaluable pediatric participants discontinued transfusions after gene therapy and were transfusion independent at the last follow-up. Younger age and persistence of higher VCN in the repopulating hematopoietic cells are associated with better outcome.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Marktel S, Scaramuzza S, Cicalese MP, et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia. Nat Med. 2019. PMID: 30664781. doi:10.1038/s41591-018-0301-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。